Recent Advances in Drug Repositioning
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 7068
Special Issue Editors
Interests: virology; biotechnology stem cell biology; drug discovery; anti-viral therapeutics; tissue regeneration
2. National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary
Interests: pharmacology; drug repositioning; pharmacokinetics; antimicrobial resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Viral infections such as influenza, HIV, hepatitis, Ebola, Dengue, and SARS-CoV have claimed millions of human lives over time. The emergence and reemergence of new viruses have raised significant concerns. Their complex multistep lifecycles allow viruses to evade the host immune response, proliferate within the host, and produce infectious progeny virions. Furthermore, with the rapid replication rate and minimal proofreading activity during replication, viruses develop mutations that enable them to develop swift resistance to therapeutic drugs. Hence, there remains a persistent need to discover novel, more efficient broad-spectrum antiviral therapeutic strategies.
The development and characterization of novel antiviral molecules from the beginning costs an average of USD 400 million to USD 2 billion per drug. The journey from the laboratory to the clinic expends more than a decade. Despite consuming extensive resources, the success rate of novel drugs is meager. The utilization of drug repurposing/recycling approaches has generated substantial interest in overcoming these drawbacks. A drastic reduction in the failure rate, which is otherwise >90%, is achieved with the drug repurposing approach. The recent exploration of the drug repurposing approach to combat the COVID-19 pandemic has further validated that reinvestigating the in-practice drugs for a new application is more beneficial than designing novel drugs.
The first successful example of drug repurposing is zidovudine (AZT), developed as an anti-cancer agent in the 1960s and later approved by the US FDA as an anti-HIV therapeutic drug in the late 1980s after fast-track clinical trials. Since then, this approach has been successfully utilized to develop effective therapeutic strategies not only against viral diseases but also against many pathological conditions, including cancer and neurodegenerative diseases.
For this Special Issue, we welcome all perspectives and high-quality research articles, including but not limited to original research articles and review articles.
Dr. Jay Trivedi
Dr. Ákos Jerzsele
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viruses
- host immune response
- drug resistance
- antiviral molecules
- drug repurposing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.